Phase 2 Results of Selinexor in Advanced De-Differentiated (DDLS) Liposarcoma (SEAL) Study: A Phase 2/3, Randomized, Double Blind, Placebo Controlled Cross-Over Study

Mrinal Gounder¹, Neeta Somaiah², Steven Attia³, Sant Chawla⁴, Victor Villalobos⁵, Bartosz Chmielowski⁶, Melissa Burgess⁷, Gary K. Schwartz⁸, Richard F. Riedel⁹, Margaret von Mehren¹⁰, Andrew J. Wagner¹¹, Edwin Choy¹², Shailendra Verma¹³, Boyd Mudenda¹⁴, Mara Sadanowicz¹⁴, Jatin Shah¹⁴, Lingling Li¹⁴, Sharon Shacham¹⁴, Michael Kauffman¹⁴, Albiruni R. Abdul Razak¹⁵

¹ Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
² MD Anderson Cancer Center, Houston, TX
³ Mayo Clinic Florida, Jacksonville, FL
⁴ Sarcoma Oncology Center, Santa Monica, CA
⁵ University of Colorado, Denver, Colorado
⁶ University of California, Los Angeles, California
⁷ University of Pittsburgh Medical Center, Pittsburgh, PA
⁸ Columbia University MC New York, NY
⁹ Duke Cancer Institute, Durham, NC
10 Fox Chase Cancer Center, Philadelphia, PA
11 Dana-Farber Cancer Institute, Boston, MA
12 Massachusetts General Hospital, Boston, MA
13 Ottawa Hospital Cancer Center, ON, Canada
14 Karyopharm Therapeutics, Newton, MA
15 Princess Margaret Cancer Centre, Toronto, Ontario
Selinexor Mechanism of Action

- Exportin 1 (XPO1) is the major nuclear export protein for tumor suppressor proteins (TSPs) (e.g. p53, pRb, IκB, p27, p21) and eIF4E-bound oncoprotein mRNAs (e.g. c-Myc, MDM2, Bcl-2, Bcl-6, cyclin D)
- Selinexor, a selective inhibitor of XPO1-mediated nuclear export (SINE) compound, reactivates multiple TSPs including p53, IκB and FOXO, reduces c-Myc levels, and overcomes MDM2-mediated p53 degradation
- Selinexor in liposarcoma:
  - CDK4 and MDM2 are amplified or overexpressed in dedifferentiated liposarcoma (DDLS) and contribute to active proliferation (Thway 2016)
  - Selinexor reactivates p53 by increasing its protein levels, locking it in the nucleus and protecting it from MDM2-dependent-degradation
  - Selinexor increases p21 protein levels. p21 binds to and inhibits the kinase activity of the cyclin D – CDK4
  - Selinexor inhibits XPO1 mediated export of eIF4E and reduces the translation of eIF4E-dependent-protooncogenes among them cyclin D
Selinexor in Advanced Liposarcoma (SEAL) is a phase 2-3, double-blind, randomized, placebo controlled, study comparing selinexor versus placebo in patients with dedifferentiated liposarcoma.

- Patients ≥18 years with relapsed/refractory locally advanced or metastatic DDLS are randomized (1:1) to receive selinexor (60 mg) or placebo twice weekly per 42 day cycle
- Randomization Stratifications: prior systemic therapies (1 vs. ≥ 2) and prior eribulin use (prior eribulin vs. no prior eribulin)
- Main Inclusion/Exclusion Criteria: Histologically confirmed DDLS (using FISH or IHC), Refractory/relapsed, Measurable disease (by CT or MRI) per RECIST v1.1. Patients with brain metastases excluded
- Phase II Primary Endpoint: Progression free survival (PFS) as determined by an independent central imaging panel using WHO criteria. Pre-specified analysis using RECIST v1.1 was also included.
  - Secondary Endpoints: Overall response rate (ORR) and Duration of response (DOR) for each arm independently according to RECIST v1.1, safety for each arm

STUDY SCHEMATIC:
# SEAL Patient Characteristics

<table>
<thead>
<tr>
<th>SEAL Patient Characteristics</th>
<th>Selinexor</th>
<th>Placebo</th>
<th>All Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enrolled¹</td>
<td>26</td>
<td>30</td>
<td>56</td>
</tr>
<tr>
<td>Median Age, Years (range)</td>
<td>55 (25 – 78)</td>
<td>64 (41-79)</td>
<td>61 (25-79)</td>
</tr>
<tr>
<td>Males : Females</td>
<td>14 M : 12 F</td>
<td>19 M : 11 F</td>
<td>33 M : 23 F</td>
</tr>
<tr>
<td>Cross-Over to Open Label Selinexor²</td>
<td>2 (8%)</td>
<td>24 (80%)</td>
<td>26 (46%)</td>
</tr>
</tbody>
</table>

## Median Number of Prior Regimens (range)

- **Doxorubicin**
  - Selinexor: 2 (1 – 7)
  - Placebo: 2 (1-9)
  - All Patients: 2 (1-9)
  - Males: 18 (69%)
  - Females: 24 (80%)
  - All Patients: 42 (75%)

- **Gemcitabine**
  - Selinexor: 12 (46%)
  - Placebo: 15 (50%)
  - All Patients: 27 (48%)

- **CDK Inhibitor**
  - Selinexor: 8 (31%)
  - Placebo: 8 (27%)
  - All Patients: 16 (29%)

- **Eribulin**
  - Selinexor: 8 (31%)
  - Placebo: 6 (20%)
  - All Patients: 14 (25%)

- **Trabectedin**
  - Selinexor: 6 (23%)
  - Placebo: 5 (17%)
  - All Patients: 11 (20%)

- **MDM2 Inhibitor**
  - Selinexor: 5 (19%)
  - Placebo: 9 (30%)
  - All Patients: 14 (25%)

- **Surgery**
  - Selinexor: 23 (88%)
  - Placebo: 28 (93%)
  - All Patients: 51 (91%)

- **Radiation**
  - Selinexor: 9 (35%)
  - Placebo: 14 (47%)
  - All Patients: 23 (41%)

---

¹Fifty-seven total patients enrolled however, one patient was deemed ineligible per protocol and was never unblinded
²Two patients on blinded selinexor crossed over to open-label selinexor due to progression based on WHO criteria, however treating PI believed these patients were deriving clinical benefit and kept treating patients with selinexor
12 patients on selinexor had dose reductions due to AEs. No deaths occurred on blinded selinexor treatment. One death (colonic perforation) was reported on blinded placebo treatment.
## SEAL PFS: WHO v. RECIST v1.1 Criteria

<table>
<thead>
<tr>
<th>Variable</th>
<th>WHO Criteria</th>
<th>RECIST v1.1 Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Measurability at baseline</strong></td>
<td>Bi-dimensional, any size, determine product of longest (LD) and shortest (SD) diameters</td>
<td>Uni-dimensional (LD only) with LD ≥1 cm. Non-measurable: All other lesions, including small lesions (LD &lt;1 cm)</td>
</tr>
<tr>
<td><strong>No. of Target Lesions Evaluated</strong></td>
<td>All lesions are considered target lesions, including small (1 cm) lesions</td>
<td>Up to 5 total target lesions (maximum 2 per organ)</td>
</tr>
<tr>
<td><strong>Progressive Disease</strong></td>
<td>≥25% increase in product (LD x SD) of one or more isolated lesions or appearance of new lesions</td>
<td>≥20% increase over smallest SUM of LDs observed (absolute increase of at least 5 mm) or appearance of new lesions</td>
</tr>
</tbody>
</table>

Comparison of WHO to RECIST v1.1 revealed that the WHO criteria, which uses a bi-dimensional evaluation of each lesion, results in the premature determination of clinically asymptomatic progression events, typically involving small lesions, while overall tumor burden was stable. This phenomenon has already been observed in tumors such as sarcoma and melanoma, which are heterogenous and have irregularly shaped lesions. Numbers of patients with PD based on WHO criteria was 2-fold higher than the number of patients that had progressive disease using RECIST v1.1 criteria (*Therasse 2000, Mazumdar 2004*).
SEAL PFS: WHO vs. RECIST v1.1

WHO Criteria
Median PFS = 1.4 Months, Selinexor and Placebo
Hazard Ratio (95% CI) = 1.02 (0.59, 1.77)
Progression Events = 25 Selinexor; 28 Placebo

RECIST v1.1 Criteria
Selinexor Median PFS = 5.5 Months
Placebo Median PFS = 2.7 Months
Hazard Ratio (95% CI) = 0.67 (0.33, 1.37)
Progression Events = 13 Selinexor; 19 Placebo

Landmark Analysis* RECIST v1.1 Criteria
Selinexor Median PFS = 5.4 Months
Placebo Median PFS = 2.7 Months
Hazard Ratio (95% CI) = 0.43 (0.15, 1.26)
Progression Events = 5 Selinexor; 10 Placebo (*in patients on study ≥45 days)

Months 0 1.3 1.4 1.6 2.8 2.9 4.2 5.6 5.8 6.6
Selinexor 25 24 21 11 10 7 4 2 − −
Placebo 29 29 25 13 10 7 6 4 1 −

Months 0 1.3 1.4 1.6 2.8 4.2 5.6 8.3 8.6
Selinexor 25 24 22 14 12 7 6 3 1
Placebo 29 29 26 14 11 7 5 1 −

Months 0 1.3 2.7 2.8 4.1 4.3 5.4 6.8 7.2
Selinexor 14 12 7 − 6 − 4 3 1
Placebo 14 11 − 7 5 3 − 1 −
Blinded Selinexor Case #1 Study: 65 y/o male originally diagnosed with retroperitoneal liposarcoma (MDM2 and CDK4 co-amplification), surgically resected. Recurrence was treated with four prior lines of therapy (1gem/doc/dox, 2trabectedin, 3dacarbazine, 4ifosfamide). Randomized to selinexor. This patient remained on treatment until disease progression at 9 months.
Placebo to Cross-Over Selinexor Case #2 Study: 61 y/o female originally diagnosed with metastatic MDM2 amplified liposarcoma in June 2008. Patient had several resections for recurrent disease and was treated with seven prior systemic therapies (1 ifosf/dox; 2 gem/doc; 3 valproic acid; 4 trabectedin; 5 palbociclib; 6 nivolumab; 7 pazopanib). Patient was randomized to placebo arm, and crossed over to selinexor upon progression. This patient remained on open label selinexor treatment until disease progression at 11 months.
Conclusions

• Phase 2 portion of the SEAL trial is now complete and the Phase 3 portion is ongoing.

• The most common adverse events of selinexor treatment are: nausea, fatigue, anorexia, and weight loss (mostly Grade 1/2). Hyponatremia and anemia are the most common Grade 3/4 adverse events.

• RECIST v1.1 may be better criteria than WHO to evaluate selinexor efficacy in DDLS; as WHO results in the premature determination of clinically asymptomatic progression events, typically involving small lesions, while overall tumor burden was stable.
  • Hazard Ratios (95% CI) comparing Selinexor to Placebo of 0.67 (0.33, 1.37) using RECIST v1.1 criteria, as compared to 1.02 (0.59, 1.77) using WHO criteria.
  • Median PFS for Selinexor and Placebo are – RECIST: 5.5 months vs. 2.7 months; WHO: 1.4 months for both.

• Improvement of PFS (RECIST v1.1) is promising and supports continuation of the Phase 3 portion of selinexor in DDLS using RECIST v1.1 criteria only.